MG-101
Based on 13 publication(s) in Google Scholar
MG-101 (ALLN) is an inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with Kis of 190, 220, 150 and 500 pM, respectively. MG-101 induces apoptosis and inhibits tumor growth, it can be used for the research of colon cancer.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 110044-82-1
- Formula: C20H37N3O4
- Molecular Weight:383.53
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Ubiquitination Compound Library
HY-L050
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protease Inhibitor Library
HY-L147
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) MG-101
More- Signal Transduct Target Ther. 2025 Dec 17;10(1):413. [Abstract]
- Science. 2021 Mar 5;371(6533):eabb2224. [Abstract]
- Nat Commun. 2025 Jan 8;16(1):496. [Abstract]
- J Genet Genomics. 2024 Oct;51(10):1020-1029. [Abstract]
- Cell Rep. 2021 Jun 29;35(13):109299. [Abstract]
- Glia. 2022 Dec;70(12):2392-2408. [Abstract]
- Int J Mol Sci. 2022 May 16;23(10):5529. [Abstract]
- J Cell Mol Med. 2020 Aug;24(16):9287-9299. [Abstract]
- Sci Rep. 2025 Jul 21;15(1):26481. [Abstract]
- Sci Rep. 2022 Jul 16;12(1):12197. [Abstract]
- Exp Cell Res. 2023 Dec 15;433(2):113859. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- bioRxiv. 2020 Jun.
Customer Validation & Images
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
WB
-
Bio/Physico-chemical Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16 | IC50 |
14.5 μM
Compound: ALLN
|
Inhibitory concentration of the compound was determined against melanoma B16 cells
Inhibitory concentration of the compound was determined against melanoma B16 cells
|
[PMID: 15634028] |
| HeLa | CC50 |
25.1 μM
Compound: ALLN
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 23357632] |
| L1210 | IC50 |
3 μM
Compound: ALLN
|
Inhibitory concentration of the compound was determined against L1210 cells
Inhibitory concentration of the compound was determined against L1210 cells
|
[PMID: 15634028] |
MG-101 (0-26 μM; 24 h) affects the growth of colon cancer HCT116 cells[1]. MG-101 (0-26 μM; 24 h) induces apoptosis of various cancer cells[1]. MG-101 (0-26 μM; 24 h) induces Bax-dependent apoptosis in HCT116 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cell line
-
Concentration:0-26 μM
-
Incubation Time:24 hours
-
Result:Anchorage-independently and significantly decreased the viability of HCT116 cells.
-
Cell Line:HCT116, RKO, SW480 and HepG2 cell lines
-
Concentration:0-26 μM
-
Incubation Time:24 hours
-
Result:Dose-dependently decreased the concentration of pro-caspase 3 and increased the concentration of cleaved-PARP in HCT116 cells. Induced apoptosis of HCT116, RKO, SW480 and HepG2 cells.
-
Cell Line:HCT116, HCT116/p53-/- and HCT116/Bax-/- cell lines
-
Concentration:0-26 μM
-
Incubation Time:24 hours
-
Result:Induced apoptosis via a Bax-dependent manner, but not via a p53-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female athymic nude mice with HCT116 cells injection[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; 10 mg/kg once daily; for 15 days
-
Result:Significantly decreased tumor weight and volume of treated mice at day 26 compared to control mice, and showed no effect on body weights.
Chemical Information
-
CAS No. 110044-82-1
-
Appearance Solid
-
Molecular Weight 383.53
-
Formula C20H37N3O4
-
Color White to light yellow
-
SMILES
O=C(N[C@H](C=O)CCCC)[C@@H](NC([C@@H](NC(C)=O)CC(C)C)=O)CC(C)C
-
Synonyms
Calpain inhibitor I; Ac-LLnL-CHO; ALLN
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]2025 Dec 17;10(1):413. PMID: 41407678 -
Science
A structure of human Scap bound to Insig-2 suggests how their interaction is regulated by sterols. [Abstract]2021 Mar 5;371(6533):eabb2224. PMID: 33446483 -
Nat Commun
Phenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone promote antiviral immune response by activating NF-ĸB. [Abstract]2025 Jan 8;16(1):496. PMID: 39779683
MG-101 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):496. [Abstract]
Real-time PCR analysis the mRNA expression of IFNs and ISGs in PBLD-overexpressing HeLa cells treated with DMSO, MG101 (20 μM) or QNZ (10 μM) or transfected with siNF-κB (10 nM) or siNC, and then infected with BPIV3 (MOI = 1), VSV (MOI = 1) or HSV-1 (MOI = 1), respectively for 24 h.
MG-101 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):496. [Abstract]
To investigate the roles of NF-κB in PBLD mediated IFN-I signaling pathway, we used two pharmacological inhibitors of NF-κB, MG-101 and QNZ. The optimal concentrations of MG-101 (20 μM) and QNZ (10 μM) were determined through cell viability assays.
-
J Genet Genomics
2024 Oct;51(10):1020-1029. PMID: 38663479 -
Cell Rep
2021 Jun 29;35(13):109299. PMID: 34192549 -
Glia
Astrocyte-specific loss of lactoferrin influences neuronal structure and function by interfering with cholesterol synthesis. [Abstract]2022 Dec;70(12):2392-2408. PMID: 35946355 -
Int J Mol Sci
Decreased Expression of Plakophilin-2 and αT-Catenin in Arrhythmogenic Right Ventricular Cardiomyopathy: Potential Markers for Diagnosis. [Abstract]2022 May 16;23(10):5529. PMID: 35628349
MG-101 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 May 16;23(10):5529. [Abstract]
Protein levels in HL-1/shLuc, shCTNNA3, and shPKP2 cardiomyocytes after MG101 (5 μM, 24 h) treatment.
-
J Cell Mol Med
Calpain-2 plays a pivotal role in the inhibitory effects of propofol against TNF-α-induced autophagy in mouse hippocampal neurons. [Abstract]2020 Aug;24(16):9287-9299. PMID: 32627970
MG-101 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Aug;24(16):9287-9299. [Abstract]
We found that TNF-α-induced calpain activation was attenuated by pre-treatment of neurons with 50 μmol/L calpain inhibitor IV (a calpain-2 selective inhibitor), 200 nmol/L NA101 (a calpain-2 selective inhibitor), 20 μmol/L calpain Inhibitor I (MG-101, a non-selective calpain inhibitor) and 50 μmol/L calpeptin (a non-selective calpain inhibitor).
-
Sci Rep
Substrate profiling of marine-derived thermotolerant cysteine protease reveals unique cleavage preferences for industrial applications. [Abstract]2025 Jul 21;15(1):26481. PMID: 40691222
MG-101 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Jul 21;15(1):26481. [Abstract]
Dose response curves of two inhibitors, leupeptin and MG101 (0.01 nM-10 μM), against globupain. The substrate Boc-QAR-amc was used. Activity was normalized to a vehicle treated sample.
-
Sci Rep
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]2022 Jul 16;12(1):12197. PMID: 35842458 -
Exp Cell Res
Cardiac ischemic preconditioning promotes cMyBP-C phosphorylation by inhibiting the calpain-mediated proteolysis. [Abstract]2023 Dec 15;433(2):113859. PMID: 38000772 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
Solvent & Solubility
DMSO : ≥ 100 mg/mL (260.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.35 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (4.35 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6074 mL | 13.0368 mL | 26.0736 mL | 65.1839 mL |
| 5 mM | 0.5215 mL | 2.6074 mL | 5.2147 mL | 13.0368 mL | |
| 10 mM | 0.2607 mL | 1.3037 mL | 2.6074 mL | 6.5184 mL | |
| 15 mM | 0.1738 mL | 0.8691 mL | 1.7382 mL | 4.3456 mL | |
| 20 mM | 0.1304 mL | 0.6518 mL | 1.3037 mL | 3.2592 mL | |
| 25 mM | 0.1043 mL | 0.5215 mL | 1.0429 mL | 2.6074 mL | |
| 30 mM | 0.0869 mL | 0.4346 mL | 0.8691 mL | 2.1728 mL | |
| 40 mM | 0.0652 mL | 0.3259 mL | 0.6518 mL | 1.6296 mL | |
| 50 mM | 0.0521 mL | 0.2607 mL | 0.5215 mL | 1.3037 mL | |
| 60 mM | 0.0435 mL | 0.2173 mL | 0.4346 mL | 1.0864 mL | |
| 80 mM | 0.0326 mL | 0.1630 mL | 0.3259 mL | 0.8148 mL | |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2607 mL | 0.6518 mL |
Powered by Bioz